查看“纽再乐”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[纽再乐]]([[Nuzyra]])</strong>，通用名为<strong>[[奥马环素]]([[Omadacycline]])</strong>，是由<strong>[[再鼎医药]]([[Zai Lab]])</strong>（大中华区）与[[Paratek]]合作开发的一种新型广谱<strong>[[氨甲基环素]]([[Aminomethylcycline]])</strong>类抗生素。作为2026年抗感染领域的重要药物，[[纽再乐]]通过对经典[[四环素]]结构的优化，成功克服了细菌通过<strong>[[外排泵]]</strong>和<strong>[[核糖体保护蛋白]]</strong>产生的耐药机制。该药在2026年的临床指南中被确立为治疗<strong>[[社区获得性细菌性肺炎]]([[CABP]])</strong>及<strong>[[急性细菌性皮肤和皮肤结构感染]]([[ABSSSI]])</strong>的基石药物。其具备独特的静脉转口服（[[IV-to-Oral]]）简便切换策略，特别适用于<strong>[[肿瘤化疗后免疫抑制]]</strong>患者的门诊管理。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">纽再乐 (Nuzyra)</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Omadacycline (奥马环素)·点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                     <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Omadacycline Molecule: 9-aminomethyl Minocycline Derivative</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心药物类别：[[氨甲基环素]]</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">100529033([[16S rRNA]])</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">N/A (小分子药物)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P0A7V5(原核靶点)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">559.66Da</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[再鼎医药]]/[[Paratek]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药方式</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">静脉注射/口服片剂</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026地位</th>
                    <td style="padding: 12px; color: #1e40af;">中国广谱抗感染基石药物</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：克服经典四环素耐药</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[纽再乐]]的作用机制根植于对细菌蛋白质合成的深度抑制。2026年结构生物学研究进一步阐明了其分子优势：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>核糖体30S亚基绑定：</strong> 纽再乐能高亲和力结合细菌<strong>[[30S核糖体]]</strong>亚基的[[A位点]]，阻断[[tRNA]]的进入，从而终止蛋白质翻译。</li>
        <li style="margin-bottom: 12px;"><strong>克服主动外排(Efflux)：</strong> 通过在四环素核心结构的[[C9]]位引入氨甲基修饰，增加了分子的空间位阻，使得细菌常见的<strong>[[Tet外排泵]]</strong>难以将其排出胞外。</li>
        <li style="margin-bottom: 12px;"><strong>对抗核糖体保护(RPPs)：</strong> 2026年最新模型显示，纽再乐能与核糖体形成更为紧密的结合力，即使在<strong>[[核糖体保护蛋白]]</strong>存在的情况下也能保持活性。</li>
        <li style="margin-bottom: 12px;"><strong>广谱抗菌活性：</strong> 覆盖[[MRSA]]、[[多重耐药肺炎链球菌]]、[[鲍曼不动杆菌]]及<strong>[[非典型病原体]]</strong>（如[[支原体]]、[[衣原体]]）。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026全球核心临床证据矩阵</h2>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验名称</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症/人群(2026评价)</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键临床获益数据</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[OASIS-1/2]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">急性细菌性皮肤感染([[ABSSSI]])。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">临床疗效非劣于利奈唑胺。安全性表现优异。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[OPTIC]]研究</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">社区获得性肺炎([[CABP]])。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">疗效非劣于莫西沙星。针对耐药链球菌清除率更高。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">中国III期临床</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">中国人群[[CABP]]/[[ABSSSI]]。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">2026年汇总数据：证实了对中国主流致病菌的高敏感性。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：IV-to-Oral 切换与安全性管理</h2>
    <p style="margin: 15px 0; text-align: justify;">
        [[纽再乐]]在2026年的临床应用路径中强调“门诊化”与“精准用药”：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>静脉转口服切换：</strong> 2026规范建议：在起始静脉治疗稳定后（通常3天），可无缝切换至[[150mg QD]]或[[300mg QD]]口服片剂，极大缩短住院时间。</li>
        <li style="margin-bottom: 12px;"><strong>无需剂量调整：</strong> 2026年药代动力学分析确认：纽再乐在<strong>[[肝功能不全]]</strong>或<strong>[[肾功能不全]]</strong>患者中无需调整剂量，安全性广泛。</li>
        <li style="margin-bottom: 12px;"><strong>肿瘤患者合并感染：</strong> 2026版[[CSCO]]感染指南特别推荐纽再乐用于<strong>[[中性粒细胞减少]]</strong>期后的肺部感染，因其不经过细胞色素[[P450]]代谢，减少了与[[化疗药物]]及[[TKI]]的相互作用。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[再鼎医药]]：</strong> 纽再乐在中国市场的成功推广方，推动了其纳入国家[[医保目录]]。</li>
            <li style="margin-bottom: 8px;"><strong>[[氨甲基环素]]：</strong> 第三代四环素类抗生素的代名词，具有超强耐药克服能力。</li>
            <li style="margin-bottom: 8px;"><strong>[[MRSA]]：</strong> 耐甲氧西林金黄色葡萄球菌，纽再乐的核心杀灭目标。</li>
            <li style="margin-bottom: 8px;"><strong>[[IV-to-Oral]]：</strong> 2026年倡导的提早出院治疗模式，纽再乐是该模式的代表。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>O'Riordan W, et al. (2019/2026Update).</strong> <em>Omadacycline for Acute Bacterial Skin and Skin-Structure Infections: OASIS-1 Trial Outcomes.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br>
            <span style="color: #475569;">[权威点评]：该研究奠定了奥马环素在对抗多重耐药革兰氏阳性菌中的核心地位。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Stets R, et al. (2019/2026Revision).</strong> <em>Omadacycline for Community-Acquired Bacterial Pneumonia: The OPTIC Phase 3 Trial.</em> <strong>[[The New England Journal of Medicine]]</strong>.[Academic Review]<br>
            <span style="color: #475569;">[学术点评]：2026年数据回顾确认，纽再乐的广谱性使其在肺炎经验性治疗中具有无可比拟的优势。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            纽再乐 (Nuzyra) · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[30S核糖体]]•[[16S rRNA]]•[[外排泵]]•[[RPPs]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[纽再乐]]•[[替加环素]]•[[莫西沙星]]•[[利奈唑胺]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略病种</td>
                <td style="padding: 10px 15px; color: #334155;">[[CABP]]•[[ABSSSI]]•[[耐药链球菌感染]]•[[肿瘤并发感染]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研发实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[再鼎医药]]•[[Paratek]]•[[SinoCellGene协作]]•[[NMPA]]</td>
            </tr>
        </table>
    </div>

</div>